Organon Canada extends the Remind Me Today! reminder program
TORONTO, Oct. 29 /PRNewswire/ - Organon Canada has extended the Remind Me Today! program - a free telephone-based reminder program designed to help women remember their Linessa(R) or Nuvaring(R) contraceptives.
In Canada, over 1.3 million women (Stat. Can., 2001) take oral contraceptives everyday and there probably isn't a woman alive who hasn't forgotten to take it at least once. Although the pill is over 99% effective with perfect use (3 births/1000), approximately 80 births occur every year through non-perfect use. (SOGC 2007)
Organon Canada understands the important relationship between successful healthcare outcomes and the use of communications technology. "We know how busy women's lives are and we want to support them by providing them with a reminder service. We are excited to be the first in the Canadian contraceptive market to be offering women this innovative and practical solution, and we are delighted by the response we have had since the launch of Remind Me Today! in February 2007," explains Meena Bhogal, senior product manager for the Organon Canada contraceptives portfolio.
Canadian women using the daily Linessa(R) birth control pill, or NuvaRing(R) - the one-a-month contraceptive ring - are taking advantage of free reminder messages delivered to their home, office or cellular phones. Remind Me Today! (http://www.remindmetoday.ca) is tailored to each woman's needs. Once registered, women choose the message they receive, the time the message is delivered and, if they opt for cell phone reminders, whether it's a text or voice message. Landline users receive voice messages to their home or office.
Continuing its commitment to high quality lifestyle products for women, Organon Canada has renewed its contract with Toronto's MEMOTEXT(R) to provide the Remind Me Today! program until 2009 and program reminder messages until 2010.
As the Canadian industry leader in 'personalized adherence solutions', MEMOTEXT(R) helps healthcare professionals, payers, health care stakeholders and providers boost bottom lines by supporting patient's efforts to comply with prescribed treatment plans and creating a strong daily link between stakeholders and patients.
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel.
Safe Harbor Statement
This press release may contain forward-looking statements. These forward-looking statements, addressing without limitation such key issues as growth strategy, future financial results, market positions, and product development, are based on current expectations of future events and circumstances and can be identified by the fact that they use words such as "will", "anticipate", "estimate", "expect", "project", "intend", "plan", "believe", "target", "forecast", and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business prospects.
Such forward-looking statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these forward-looking statements. Organon BioSciences undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or circumstances, or otherwise.
The forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Organon BioSciences' business, particularly but without limitation including general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.
Copyright©2007 PR Newswire.
All rights reserved